PLT VASP/P2Y12

    default
    Référence
    7014
    Statut
    CE
    Sample
    30 µl de sang total citraté
    Quantité
    10 tests
    Detection
    Fluorescence
    Application
    Kits pour la Cytométrie de flux
    Composition

    - Diluant. - PGE1 - PGE1 +ADP - Fixateur - Anticorps monoclonal anti VASP-P - Contrôle isotypique négatif - Réactif de révélation-FITC + contre-marqueur plaquettaire (CD61-PE).

    L'échantillon sanguin est incubé parallèlement en présence de PGE1 seule ou de PGE1+ ADP. Aprés une perméabilisation cellulaire, la molécule VASP sous forme phosphorylée est marquée en immunofluorescence indirecte sans lavage par un anticorps monoclonal spécifique. L'analyse en cytométrie en flux , en double couleur , permet de comparer les deux conditions testées et d'évaluer, pour l'échantillon analysé, la capacité de l'ADP à inhiber cette phosphorylation.

    Date Nom du document Téléchargement
    01/03/2015 Package insert PLT VASP P2Y12 DE (500.52 KB)
    EN (175.26 KB)
    ES (543.38 KB)
    FR (243.07 KB)
    IT (526.13 KB)
    PT (530.45 KB)
    08/06/2010 Flyer PLT VASP P2Y12 EN (592.82 KB)
    Auteur Titre Année d'édition Revue
    Barragan P et al.
    Resistance to thienopyridines : clinical detection of coronary stent thrombosis by monitoring of vasodilatator-stimulated phosphoprotein phosphorylation
    2003
    Cathet Cardiovasc Intervent
    Aleil B et al.
    Flow cytometry analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
    2005
    J Thromb Haemost
    Aleil B et al.
    High stability of blood samples for flowcytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease
    2005
    Thromb Haemost.
    Aleil B and Gachet C
    Inter-individual variability in the response to clopidogrel
    2005
    Archives des Maladies du Coeur et des Vaisseaux
    Gurbel PA et al.
    Clopidogrel Effect on Platelet REactivity in Patients With Stent Thrombosis, Results of the CREST Study
    2005
    J Am Coll Cardiol
    Montalescot G et al.
    A randomized comparison of high clopidogrel loading doses in patients with non -ST-Segment elevation Acute coronary syndromes
    2006
    JACC
    Gilart M.et al.
    Influence of omeprazol on the anti platelet action of clopidogrel associated to aspirin
    2006
    J Thromb Haemost
    Bura A et al.
    Role of the P2Y12 gene polymorphism in the platelet responsiveness to clopidogrel in healty subjects
    2006
    J Thromb Haemost
    Hulot JS et al.
    Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    2006
    Blood
    Cauwenberghs et al.
    Plasma ectonucleotidases prevent desensitization of purinergic receptors in stored platelets: importance for platelet activity during thrombus formation
    2006
    Transfusion
    Pampuch et al.
    Comparison of VASP phosphorylation assay to light transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor
    2006
    Thromb Haemost.
    Gurbel PA and Tantry U
    Drug insight : clopidogrel responsiveness
    2006
    Nat Clin Pract Cardiovasc Med
    Aleil B et al.
    Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases
    2007
    J Thromb Haemost
    Angiolilo DJ et al.
    Randomized comparison of a high clopidogrel maintenance dose in patients with Diabetis mellitus and coronary artery disease
    2007
    Circulation
    van Werkum et al.
    The flow cytometric VASP assay can be used to determined the effectiveness of clopidogrel in patients treated with Abciximab
    2007
    J Thromb Haemost
    Cuisset T et al.
    Lack of association between the 807C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome
    2007
    Thromb Haemost.
    Mueller Tet al.
    Utility of whole blood impedance aggregometry for the assessment of clopidogrel action using the novel Multiplate® analyzer -comparison with two flow cytometric methods"
    2007
    Thromb Res
    Cuisset T. et al.
    Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome
    2007
    Thromb Res
    Bonello L et al.
    VASP phosphorylation analysis prior to percutaneous coronary intervention for exclusion of post-procedural major adverse cardiovascular events
    2007
    J Thromb Haemost
    Cattaneo M et al.
    Platelet P2 receptors: old and new targets for antithrombotic drugs
    2007
    Cardiovascular Therapy
    Gurbel PA et al.
    Assessment of clopidogrel responsiveness : measurements of maximum platelet agreggation, final platelet agreggation and their correlation with Vasodilator stimulated phosphoprotein in resistant patients
    2007
    Thromb Res
    Schumacher WA et al.
    Biomarker optimization to track antithrombotic and hemostatic effects of clopidogrel
    2007
    J Pharmacol Exp Ther.
    De Gaetano and Cerletti.
    Platelet function, antiplatelet therapy and clinicla outcomes : to test or not to test ?
    2007
    J Thromb Haemost
    Paniccia R et al.
    Different methodologies for evaluating the effect of clopidogrel on platelet function in high isk coronary artery disease patients
    2007
    J Thromb Haemost
    Dropinski et al.
    The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin
    2007
    Thromb Haemost.
    Fontana P et al.
    Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopicogrel responsiveness
    2007
    Thromb Haemost.
    Morel O et al.
    Impaired platelet responsiveness to clopidogrel identified by flow cytometric VASP phosphorylation in patients with subacute stent thrombosis
    2007
    Thromb Haemost.
    Frere C et al.
    ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome
    2007
    Thromb Haemost.
    Gurbel PA et al.
    Platelet function monitoring in patients with coronary artery disease
    2007
    JACC
    Blindt R et al.
    The Significance of Vasodilator-Stimulated Phosphoprotein for Risk Stratification of Stent Thrombosis
    2007
    Thromb Haemost.
    Eli Lev et al.
    Effect of caffeine on platelet inhibition by clopidogrel in healthy subjects and patients with coronary artery disease
    2007
    Am Heart J
    Schäfer A et al.
    Late thrombosis of a drug-eluting stent during combined anti-platelet therapy in a clopidogrel nonresponsive diabetic patient: Shall we routinely test platelet function ?
    2007
    Thromb Haemost.
    Wiviott SD et al.
    Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
    2007
    Circulation
    Wallentin L et al.
    Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
    2008
    European Heart Journal
    Sbrana S et al.
    Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation
    2008
    Cytometry Part B
    Gilard M. et al.
    Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin: The Randomized, Double-Blind OCLA (Omeprazole CLopidogrel Aspirin) Study
    2008
    J. Am. Coll. Cardiol.
    Gurbel PA et al.
    Omeprazole A Possible New Candidate Influencing the Antiplatelet Effect of Clopidogrel
    2008
    J. Am. Coll. Cardiol.
    Frere C et al.
    Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome
    2008
    Am J Cardiol.
    Angiolillo DJ et al.
    Functional Effects of High Clopidogrel Maintenance Dosing in Patients With Inadequate Platelet Inhibition onStandard Dose Treatment
    2008
    Am J Cardiol.
    Bonello L et al.
    Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study
    2008
    J. Am. Coll. Cardiol.
    Jakubowski J et al.
    A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry
    2008
    Thromb Haemost.
    Yano Y et al.
    Determinants of thrombin generation,fibrinolytic activity, and endothelial dysfunctionin dual-antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow’s triad
    2008
    Eur Heart J.
    Umemura K et al,
    The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects
    2008
    J Thromb Haemost
    Bonello L et al,
    A threshold of platelet reactivity for ischaemic events?
    2008
    Eur Heart J.
    Bonello L et al,
    Two strategies of clopidogrel loading dose to decrease the frequency of clopidogrel resistance in patients undergoing percutaneous coronary intervention
    2008
    Thromb Res
    Michelson A et al.
    P2Y12 Antagonism: Promises and Challenges
    2008
    ATVB
    Angiolillo DJ et al.
    A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study
    2008
    Eur Heart J.
    Schäfer A et al.
    ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay
    2008
    Thromb Haemost
    Siller-Matula JM et al.
    Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel
    2008
    J. Am. Coll. Cardiol.
    Morel O et al.
    Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
    2008
    Thromb Haemost
    Djukanovic N. et al.
    Thienopyridine Resistance Among Patients Undergoing Intracoronary Stent Implantation and Treated With Dual Antiplatelet Therapy: Assessment of Some Modifying Factors
    2008
    J Pharmacol Sci
    De Miguel A et al.
    Clinical implications of clopidogrel resistance
    2008
    Thromb Haemost.
    Weber AA et al.
    Methods to Evaluate the Pharmacology of Oral Antiplatelet Drugs
    2008
    Herz
    Aleil B al.
    Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention"
    2008
    J Am Coll Cardiol Intv
    Erlinge D et al.
    Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo
    2008
    J. Am. Coll. Cardiol.
    Cayla G et al.
    Flow cytometric assessment of vasodilator-stimulated phosphoprotein: Prognostic value of recurrent cardiovascular events after acute coronary syndromes
    2008
    Arch Cardiovasc Dis.
    Bonello L et al.
    Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
    2009
    Am J Cardiol.
    Lortie E. et al.
    Clopidogrel induces an acute hemostatic deficit and increases intra abdominal bleeding in rabbits
    2009
    Thromb Res
    Siller-Matula JM et al.
    The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation
    2009
    Thromb Res
    Bonello L et al.
    Emergence of the Concept of Platelet Reactivity Monitoring of Response to Thienopyridines
    2009
    Heart
    Hogberg C. et al .
    Mild hypothermia does not attenuate platelet aggregation and may even increase ADP-stimulated platelet aggregation after clopidogrel treatment
    2009
    Thrombosis Journal
    Cuisset T et al.
    Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response
    2009
    Thromb Res.
    Varenhorst C et al.
    Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
    2009
    Eur Heart J
    Motovska Z et al.
    High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial
    2009
    Blood Coagul Fibrinolysis
    Michelson A. et al
    Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial
    2009
    European Heart Journal
    Cuisset T et al.
    Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non ST-elevation acute coronay syndrome
    2009
    EuroIntervention
    Aleil B. et al.
    CYP2C19*2 polymorphism is not the sole determinant of the response to clopidogrel: implications for its monitoring
    2009
    J Thromb Haemost
    Siller-Matula JM et al.
    Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    2009
    Am Heart J
    Cuisset T et al.
    Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose
    2009
    J. Am. Coll. Cardiol.
    Alström U et al.
    Platelet inhibition assessed with VerifyNow, flow cytometry and PlateletMapping in patients undergoing heart surgery
    2009
    Thromb Res
    Siller-Matula JM et al.
    Cross validation of the Multiple Electrode Aggregometry
    2009
    Thromb Haemost.
    Gremmel T et al.
    Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation
    2009
    Thromb Haemost.
    James S et al.
    Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    2009
    Am Heart J
    Gurbel PA and Tantry U.
    Selecting Optimal Antiplatelet Therapy Based on Platelet Function Monitoring in Patients With Coronary Artery Disease
    2009
    Curr Treat Op Cardio Med
    Frere C et al.
    CYP2C19*17 Allele is associated with Better Platelet Response to Clopidogrel in patients admitted for Non-ST Acute Coronary Syndrome
    2009
    J Thromb Haemost.
    Motovska Z et al.
    Clopidogrel resistance Live" - the risk of stent thrombosis should be evaluated before procedures
    2009
    Thrombosis J
    Motovska Z et al.
    Optimal pretreatment timing for high load dosing (600 mg) of clopidogrel before planned percutaneous coronary intervention for maximal antiplatelet effectiveness
    2010
    Int J Cardiol.
    Palmerini T. et al,
    A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study
    2010
    Thromb Res
    Bonello L et al.
    Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism
    2010
    Int J cardiol.
    Bonello L et al.
    Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients
    2010
    Thromb Res.
    von Beckerath N et al.
    Assessment of platelet response to clopidogrel with multiple electrode aggregometry, the VerifyNow P2Y12 analyzer and platelet vasodilator-stimulated phosphoprotein flow cytometry
    2010
    Blood Coagulation and Fibrinolysis
    Gurbel PA et al.
    The Effect of Elinogrel on High Platelet Reactivity During Dual Antiplatelet Therapy and the Relation to CYP 2C19*2 Genotype:First Experience in Patients
    2010
    J Thromb Haemost.
    Bellemain-Appaix A et al.
    Slow Response to Clopidogrel Predicts Low Response
    2010
    J. Am. Coll. Cardiol.
    Metzmer H et al.
    Premature preoperative discontinuation of antiplatelet drug therapy in cardiovascular risk patients: a preliminary study on the role of P2Y12 receptor monitoring
    2010
    Eur J Anaesthesiol.
    Cuisset T et al.
    Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting
    2010
    Archives of Cardiovascular Disease
    Gurbel PAet al.
    Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies. The RESPOND Study
    2010
    Circulation
    Small DS et al.
    Pharmacodynamics and Pharmacokinetics of Single Doses of Prasugrel 30 mg and Clopidogrel 300 mg in Healthy Chinese and White Volunteers: An Open-Label Trial
    2010
    Clin Ther.
    Flierl U et al.
    The novel P2Y12 antagonist AZD6140 rapidly and reversibly reduces platelet activation in diabetic rats
    2010
    Thromb Res
    Bouman HJ et al.
    Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel
    2010
    J Thromb Haemost.
    Gajos G et al.
    Effects of Polyunsaturated Omega-3 Fatty Acids on Responsiveness to Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
    2010
    J. Am. Coll. Cardiol.
    El Ghannudi S
    Impact of P2Y12 Inhibition by Clopidogrel on Cardiovascular Mortality in Unselected Patients Treated by Percutaneous Coronary Angioplasty
    2010
    J Am Coll Cardiol Intv
    Bonello L et al.
    Clopidogrel Loading Dose Adjustment According to Platelet Reactivity Monitoring in Patients Carrying the 2C19 2* Loss of Function Polymorphism
    2010
    J. Am. Coll. Cardiol.
    Delavenne X et al.
    Is there really a relationship between the plasma concentration of the active metabolite of clopidogrel and the results of platelet function tests?
    2010
    J Thromb Haemost. 
    Aradi D et al.
    Comparison of conventional aggregomerty with VASP for monitoring P2Y12-specifc platelet inhibition
    2010
    Platelets
    Zighetti ML et al.
    Usefulness of a flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of patients with genetic defects of the platelet P2y12 receptor for ADP
    2010
    J Thromb Haemost. 
    Bonello L et al.
    Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate
    2010
    J. Am Coll Cardiol.
    Storey RF et al.
    Inhibitory Effects of Ticagrelor Compared With Clopidogrel on Platelet Function in Patients With Acute Coronary Syndromes The PLATO (PLATelet inhibition and patient Outcomes) PLATELET Substudy
    2010
    J. Am. Coll. Cardiol.
    Angiolillo DJ et al.
    Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study
    2010
    J. Am. Coll. Cardiol.
    Bonello L et al.
    Level of P2Y12-ADP receptor blockade during percutaneous coronary intervention predicts the extent of endothelial injury,assessed by CEC measurement
    2010
    J. Am. Coll. Cardiol.
    Bjellanda TW et al.
    Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest
    2010
    Resuscitation
    Fu Q et al.
    Comparison of platelet P2Y12 ADP receptor mediated pathway inhibition in triple versus dual antiplatelet therapy as assessed by VASP phosphorylation in japanese patients undergoing coronary stenting
    2010
    Int Heart J.
    Fontana P et al.
    Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study
    2010
    J Thromb Haemost.
    Ferreiro JL et al.
    Pharmacodynamic effects of concomitant versus stagerred clopidogrel and omeprazole intake
    2010
    Circ Cardiovasc Interv.
    Tantry U et al.
    First Analysis of the Relation Between CYP2C19 Genotype and Pharmacodynamics in Patients Treated With Ticagrelor Versus Clopidogrel. The ONSET/OFFSET and RESPOND Genotype Studies
    2010
    Circ Cardiovasc Genet.
    Osmancik P et al.
    A comparison of the VASP index between patients with hemodynamically complicated and uncomplicated acute myocardial infarction"
    2010
    Catheter Cardiovasc Interv.
    Kalantzi KI et al.
    Clopidogrel differentially affects platelet-mediated thrombosis and inflammatoryresponse in patients with acute coronary syndromes
    2011
    J Thromb Haemost.
    Petrucci G et al.
    Prostaglandin E2 Differentially Modulates Human Platelet Function through the Prostanoid EP2 and EP3 Receptors
    2011
    JPET
    Morel O et al.
    Cardiovascular Mortality in Chronic Kidney Disease Patients Undergoing Percutaneous Coronary Intervention Is Mainly Related to Impaired P2Y12 Inhibition by Clopidogrel
    2011
    J. Am. Coll. Cardiol.
    Ueno M et al.
    Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease
    2011
    Thromb Haemost
    Angiolillo DJ et al.
    Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
    2011
    Thromb Haemost
    Freynhofer MK et al.
    Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for predictionof postprocedural major adverse cardiovascular events
    2011
    Thromb Haemost
    Motovska Z et al.
    Factors Influencing Clopidogrel Efficacy in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention: Statin's Advantage and the Smoking
    2009
    J Cardiovasc Pharmacol
    Mani H. et al.
    Platelet function testing in hirudin and BAPA anticoagulated blood
    2011
    Clin Chem Lab Med
    Szymezak J. et al.
    High on-clopidogrel platelet reactivity: Genotyping can help to optimize antiplatelet treatment
    2011
    Thromb Res
    Pettersen A. et al.
    The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel
    2011
    Thrombosis Journal
    Prüller F. et al.
    Low platelet reactivity is recoverd by transfusion of stored platelets: A healthy volunteer in vivo study
    2011
    J Thromb Haemost
    Wang XD. et al.
    Modifying Clopidogrel Maintenance Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Improves Clinical Outcome in Patients With Clopidogrel Resistance
    2011
    Clin. Cardiol.
    Frelinger A. et al.
    Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications
    2011
    J. Am. Coll. Cardiol.
    Angiolillo DJ et al.
    Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy
    2011
    Thromb Haemost.
    Storey RF et al.
    Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared to clopidogrel in patients with high antiplatelet responses
    2011
    J Thromb Haemost
    Fontana P et al.
    Relationship between paraoxonase-1 activity, its Q192R genetic variant and clopidogrel responsiveness in the ADRIE study
    2011
    J Thromb Haemost
    Fernando H et al.
    Randomised Double Blind Placebo Controlled Crossover Study to Determine the Effects of Esomeprazole on Inhibition of Platelet Function by Clopidogrel
    2011
    J Thromb Haemost
    Bonello L et al.
    High On-Treatment Platelet Reactivity After Prasugrel Loading Dose and Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes
    2011
    J. Am. Coll. Cardiol.
    Ferreiro JL et al.
    Pharmacodynamic evalutation of pentaprazole therapy on cloppidogrel effect
    2011
    Circ Cardiovasc Interv.
    Ferreiro JL et al.
    Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
    2011
    Rev Esp Cardiol.
    Ueno M et al.
    Impact of Pentoxifylline on Platelet Function Profiles in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel
    2011
    J Am Coll Cardiol Intv
    Bliden KP et al.
    The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: Combined analysis of the ONSET/OFFSET and RESPOND studies
    2011
    Am Heart J.
    Grdinic A et al.
    PCI and clopidogrel: antiplatelet responsiveness and patient characteristics
    2011
    Acta Cardiol.
    Gaglia MA Jr et al.
    Relation of Body Mass Index to On-Treatment (Clopidogrel + Aspirin) Platelet Reactivity
    2011
    Am J Cardiol.
    Mega J.L et al.
    Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease
    2011
    JAMA
    Tsoumani ME
    Antiplatelet Efficacy of Long-Term Treatment With Clopidogrel Besylate in Patients With a History of Acute Coronary Syndrome: Comparison With Clopidogrel Hydrogen Sulfate
    2011
    Angiology
    Wang X.D et al.
    Modified clopidogrel loading dose according to platelet reactivity monitoring in patients carrying ABCB1 variant alleles in patients with clopidogrel resistance
    2012
    Eur J Int Med
    Kobsar A et al.
    The thrombin inhibitors, hirudin und Refludan®, activate the soluble guanylyl cyclase and the cGMP pathway in washed human platelets
    2012
    Thromb Haemost.
    Jeong YH. et al.
    High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cutoff of VASP-P platelet reactivity index too low?"
    2012
    J Thromb Haemost
    Frelinger A.L. et al,
    A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers
    2012
    J. Am. Coll. Cardiol.
    Reny J.L. et al.
    Influence of the paraoxonase-1 Q192R genetic variant on clopidogrel responsiveness and recurrent cardiovascular events: a systematic review and meta-analysis
    2012
    J Thromb Haemost
    Tello-Montoliu A.et al.
    Pharmacodynamic Effects of Prasugrel Dosing Regimens in Patients on Maintenance Prasugrel Therapy
    2012
    J. Am. Coll. Cardiol.
    Ferreiro J.L.et al.
    Impact of Adjunctive Cilostazol Therapy Versus High Maintenance Dose of Clopidogrel in Suboptimal Responders With Diabetes Mellitus
    2012
    Rev Esp Cardiol.
    Aradi D et al.
    Justification of 150 mg clopidogrel in patients with high on-clopidogrel platelet reactivity
    2012
    Eur J Clin Invest.
    Yokoi H et al.
    Pharmacodynamic assessment of a novel P2Y12 receptor antagonist in Japanese patients with coronary artery disease undergoing elective percutaneous coronary intervention
    2012
    Thromb Res
    Bonello L. et al
    Relationship between post-treatment platelet reactivity and ischemic and bleeding events at one year follow-up in patients receiving prasugrel
    2012
    J Thromb Haemost
    Liang Y et al
    Relation between clopidogrel active metabolite levels and different platelet aggregation methods in patients receiving clopidogrel and aspirin
    2012
    J Thromb Thrombolysis
    Bonello L. et al
    Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction
    2012
    Thromb Haemost.
    Bonello L. et al
    Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade
    2012
    Thromb Res
    Erlinge D. et al
    Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients
    2012
    J Am Coll Cardiol
    Suryadevara S. et al
    Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patientswith type 2 diabetes mellitus
    2012
    Thromb Haemost
    Cuisset T. et al
    CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome
    2012
    J Am Coll Cardiol Intv
    Chang H et al
    Modified Diadenosine Tetraphosphates with Dual Specificity for P2Y1 and P2Y12 are Potent Antagonists of ADP-induced Platelet Activation
    2012
    J Thromb Haemost
    Tello-Montoliu A et al
    Impact of renal function on clopidogrel-induced antiplatelet effects in coronary artery disease patients without diabetes mellitus
    2012
    J Thromb Thrombolysis
    Morel et al
    The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
    2012
    Thromb Haemost.
    Grosdidier C et al.
    Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications
    2013
    Am J Cardiol.
    Gremmel T et al.
    Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation
    2013
    Transl Res.
    Frelinger A.L et al.
    Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-medications (Including Proton Pump Inhibitors), and Pre-existent Variability in Platelet F
    2013
    J Am Coll Cardiol
    Gaglia MA et al.
    Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity
    2013
    Cardiovasc Revasc Med.
    Wun T et al.
    A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease
    2013
    J Hematol Oncol.
    Delavenne X et al.
    Investigation of drug–drug interactions between clopidogrel and fluoxetine
    2013
    Fundam. Clin. Pharmacol.
    Kerneis M et al.
    Switching Acute Coronary Syndrome Patients From Prasugrel to Clopidogrel
    2013
    J Am Coll Cardiol Intv
    Ferreiro JL et al.
    Impact of Prasugrel Reload Dosing Regimens on High On-Treatment Platelet Reactivity Rates in Patients on Maintenance Prasugrel Therapy
    2013
    J Am Coll Cardiol
    Mazur P. et al
    Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral arterial disease
    2013
    Platelets
    Nakata T et al
    Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation
    2013
    Circ. J
    Yano H et al
    Influence of Omeprazole and Famotidine on the Antiplatelet Effects of Clopidogrel in Addition to Aspirin
    2012
    Circ J.
    Erlinge D. et al.
    Prasugrel 5-mg in the very elderly attenuates platelet inhibition but maintains noninferiority
    2013
    J Am Coll Cardiol
    Laine M. et al.
    Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention
    2013
    Thromb Res.
    Kim I.S. et al.
    Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in
    2013
    Am Heart J
    El-Halabi MM et al.
    CYP2C19 Genetic Polymorphism, Rabeprazole and Esomeprazole Have no Effect on the Anti-Platelet Action of Clopidogrel
    2013
    J Cardiovasc Pharmacol.
    Fontana P et al.
    Tailored Thienopyridine Therapy: No Urgency for CYP2C19 Genotyping
    2013
    J Am Heart Assoc.
    Gurbel PA et al.
    The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and Prasugrel: The PARADOX Study
    2013
    J Am Coll Cardiol.
    Gremmel T et al.
    Response to antiplatelet therapy is independent of endogenous thrombin generation potential
    2013
    Thromb Res.
    Tello-Montoliu M. et al.
    Impact of aspirin dose on adenosine diphosphate-mediated platelet activity Results of an in vitro pilot investigation
    2013
    Thromb Haemost
    Bonello L. et al.
    A randomized trial of platelet reactivity monitoring-adjusted clopidogrel therapy versus prasugrel therapy to reduce high on-treatment platelet reactivity
    2013
    Int J Cardiol.
    Cuisset T. et al
    Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine
    2013
    J Am Coll Cardiol
    Saucedo JF. et al
    Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: Insights from the switching
    2013
    Thromb Haemost
    Tantry U.S.
    Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding
    2013
    J Am Coll Cardiol.
    Aradi D et al
    Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention
    2014
    Eur Heart J.
    Laine M et al
    Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndrome
    2014
    Thromb Haemost
    Darlington A et al
    Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery
    2014
    Thromb Haemost
    Patel Y.M. et al
    A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in PAR-1 in a patient with chronic bleeding
    2014
    J Thromb Haemost
    Samoš M et al
    Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis
    2014
    Am J Emerg Med
    Wisman P.P et al
    Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and
    2014
    J Thromb Haemost
    Lhermusier T et al
    Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
    2014
    J Interv Cardiol.
    Jakubowski JA et al
    The influence of body size on the pharmacodynamic and pharmacokinetic response to clopidogrel and prasugrel: A retrospective analysis of the FEATHER study.
    2014
    Thromb Res.
    Timur AA, et al
    Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy
    2014
    Thromb Res.
    Tang N et al.
    The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese
    2015
    Scand J Clin Lab Invest
    Siller-Matula J. M. et al
    How to improve the concept of individualised antiplatelet therapy with P2Y12 receptor inhibitors – is an algorithm the answer?
    2015
    Thromb Haemost
    Aradi D. et al
    Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention
    2015
    Eur Heart J
    Danese E. et al
    Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry
    2015
    J Thromb Haemost
    Bagoly Z. et al
    How to test the effect of aspirin and clopidogrel in patients on dual antiplatelet therapy?
    2016
    Platelets
    Bonello L. et al
    Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective study
    2015
    Int J Cardiol
    Danese E. et al
    Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry
    2016
    J Thromb Haemost.
    Storey R.F. et al
    Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial
    2016
    J Am Coll Cardiol
    Rollini F. et al
    Impact of timing from blood sampling to pharmacodynamic assessment on measures of platelet reactivity in patients treated with P2Y12 receptor inhibitors
    2016
    Thromb Haemost
    Umemura K et al
    Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
    2016
    Drug Metab Pharmacokinet
    Franchi F. et al
    Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study
    2016
    Circulation
    Umemura K et al
    Pharmacokinetics and pharmacodynamics of prasugrel in healthy Japanese subjects
    2016
    Drug Metab Pharmacokinet
    Baumann M. et al.
    The potency of selatogrel, a reversible antagonist of the P2Y12 receptor, is affected by calcium concentration.
    2021
    Platelets